HYPERGLYCEMIA AND ADVERSE PREGNANCY OUTCOME (HAPO)

高血糖和不良妊娠结局 (HAPO)

• 批准号: 7378084
• 负责人: Patrick Catalano
• 金额: $ 0.44万
• 依托单位: CASE WESTERN RESERVE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7378084
• 关键词: HYPERGLYCEMIA; ADVERSE; PREGNANCY; OUTCOME; HAPO

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a federally funded prospective multi-center trial addressing the effect of hyperglycemia on pregnancy outcome (HAPO). The specific aims are to examine glucose tolerance in a large, heterogeneous, multinational, multi-cultural, ethnically diverse cohort of women in the third trimester of gestation with medical caregivers "blinded" to status of glucose tolerance, and to derive internationally acceptable criteria for the diagnosis and classification of gestational diabetes mellitus that are based on the specific relationships between maternal hyperglycemia and the risk of specific adverse outcomes. Pregnant women will be recruited in early gestation to participate. Those who give informed consent will provide historical and antenatal data and undergo metabolic evaluation (75g OGTT and measurement of hemoglobin A1C at approximately 28 weeks gestation). Cord blood will be collected at delivery for assessment of fetal beta-cell function; neonatal hyperglycemia will be determined at one hour of life; neonatal anthropometrics measured within 24 hours; and data on delivery and neonatal outcomes will be recorded.

该子项目是利用 NIH/NCRR 资助的中心拨款提供的资源的众多研究子项目之一。子项目和研究者 (PI) 可能已从另一个 NIH 来源获得主要资金，因此可以在其他 CRISP 条目中得到体现。列出的机构是中心的机构，不一定是研究者的机构。这是一项联邦政府资助的前瞻性多中心试验，旨在解决高血糖对妊娠结局 (HAPO) 的影响。具体目标是在妊娠晚期的大型、异质、跨国、多文化、种族多样化的妇女群体中检查葡萄糖耐量，而医疗护理人员对葡萄糖耐量状况“不知情”，并根据母亲与孕妇之间的具体关系得出国际上可接受的妊娠期糖尿病的诊断和分类标准。 高血糖和特定不良后果的风险。将招募妊娠早期的孕妇参加。知情同意者将提供历史和产前数据，并接受代谢评估（75g OGTT 和妊娠约 28 周时测量糖化血红蛋白）。将在分娩时收集脐带血以评估胎儿β细胞功能；新生儿高血糖将在出生后一小时测定； 24小时内测量新生儿人体测量数据；并将记录有关分娩和新生儿结局的数据。